The Quarter story
The two most recent quarterly results, compared side-by-side.
Marksans Pharma delivers strong margin expansion and cash generation, though US market share faces headwinds.
EBITDA margin expands from 16.1% in Q1 FY26 to 25.3% in Q1 FY27, showing strong pricing power.
US & North America market share falls from 52.8% in Q1 FY26 to 44.9% in Q1 FY27, indicating competitive pressure.
Cash balance grows from ₹711 Cr in Q1 FY26 to ₹1,058 Cr in Q1 FY27, ensuring solid liquidity.
US & North America revenue drops from ₹412.4 Cr in Q3 FY26 to ₹377.2 Cr in Q1 FY27, signaling regional softening.
UK & Europe revenue climbs from ₹203.8 Cr in Q1 FY26 to ₹356 Cr in Q1 FY27, driving top-line growth.
Finance costs increase from ₹6.1 Cr in Q1 FY26 to ₹7.0 Cr in Q1 FY27, adding to operational expenses.
Working capital cycle shortens from 159 days in Q1 FY26 to 132 days in Q1 FY27, improving cash conversion.
Rest of World revenue share declines from 3.7% in Q2 FY26 to 2.4% in Q1 FY27, reducing diversification benefits.
Net profit rises from ₹58.2 Cr in Q1 FY26 to ₹159.4 Cr in Q1 FY27, confirming consistent earnings delivery.
Tax expenses rise from ₹18.4 Cr in Q1 FY26 to ₹47.2 Cr in Q1 FY27, reflecting a higher effective tax burden.
NSE
BSE
